DSGN
HEALTHCAREDesign Therapeutics Inc
$14.55+1.14 (+8.50%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DSGN Today?
No stock-specific AI insight has been generated for DSGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.11$17.25
$14.55
Fundamentals
Market Cap$909M
P/E Ratio—
EPS$-1.20
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume783K
Avg Volume (10D)—
Shares Outstanding62.5M
DSGN News
20 articles- Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...Yahoo Finance·Apr 29, 2026
- Design Therapeutics Q1 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business UpdatesYahoo Finance·Apr 28, 2026
- We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business GrowthYahoo Finance·Apr 11, 2026
- Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 ProgramMarketbeat·Mar 15, 2026
- Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business UpdatesYahoo Finance·Mar 9, 2026
- Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer ConferenceMarketbeat·Feb 26, 2026
- Design Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 18, 2026
- Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC SaysYahoo Finance·Nov 20, 2025
- Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More247 Wall St·Nov 20, 2025
- Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 5, 2025
- Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth PlansYahoo Finance·Nov 2, 2025
- Design Therapeutics Appoints Justin Gover to Board of DirectorsYahoo Finance·Sep 10, 2025
- Design Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceYahoo Finance·Aug 27, 2025
- KORU Medical Systems And 2 Other Penny Stocks To Watch For GrowthYahoo Finance·Aug 12, 2025
- Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 7, 2025
- Penny Stocks To Watch In July 2025Yahoo Finance·Jul 10, 2025
- Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2Yahoo Finance·Jun 4, 2025
- Design Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2025
- 3 Penny Stocks With Market Caps As Low As $70M To WatchYahoo Finance·May 22, 2025
All 20 articles loaded
Price Data
Open$13.34
Previous Close$13.41
Day High$13.78
Day Low$13.19
52 Week High$17.25
52 Week Low$3.11
52-Week Range
$3.11$17.25
$14.55
Fundamentals
Market Cap$909M
P/E Ratio—
EPS$-1.20
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume783K
Avg Volume (10D)—
Shares Outstanding62.5M
About Design Therapeutics Inc
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—